VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Today Multiplicom and IFFMEDIC announced that IFFMEDIC will act as Multiplicom's agent for the marketing and sales of its molecular diagnostic kits in Central Europe. This agreement is in line with Multiplicom’s strategy to improve access to innovative molecular genetic tests as well as providing expert technical support to medical genetics labs.
Multiplicom is a Belgian diagnostics company, specialized in the design, development, production, and commercialization of innovative molecular genetic tests based on next generation sequencing. IFFMEDIC is a Germany-based company focusing on marketing and sales of diagnostics. Both companies today signed an agreement under which they will work closely together to promote Multiplicom's products, to close sales agreements, and to provide expert support to customers throughout Germany, Austria, and Eastern Europe. Whereas Multiplicom was already selling products to key opinion leaders in Germany, the parties underline the strategic importance of this partnership for the further development of these diagnostic markets by regular visits to the growing list of prospects and customers.
Dirk Pollet, CEO of Multiplicom states, “This agreement with IFFMEDIC is key in our marketing and sales strategy. Germany is a major market where massive parallel sequencing based molecular diagnostics is entering clinical routine. We are delighted to team up with IFFMEDIC since they are close to the key opinion leaders, the market, and major customers in these regions.” Luc Segers, VP Marketing and Sales for Multiplicom adds, “Both teams will work closely together in the market place to sign up customers and provide expert technical support."
Andreas Iffland, General Manager IFFMEDIC notes, "The market entry of the next generation of genetic cancer tests and our intensive marketing and product development collaboration with Multiplicom will be the key strategy for our sales, customer service, and marketing teams across Central Europe."
Multiplicom produces molecular diagnostic kits that enable clinical laboratories to perform profitable testing for personalized medicine. The company was created in 2011 as a spin-off by the University of Antwerp and VIB.
Multiplicom develops, manufactures and commercializes leading-edge and easy-to-use genetic test kits, based on the latest molecular diagnostic technologies. The successful introduction of its kits in medical genetics labs proves they are the solution to an increasing demand for nucleic acid based testing that is driven by the scientific evidence that links genetic information to health and disease.
IFFMEDIC GmbH (www.iffmedic.com) is a Germany-based privately held company with a dedicated Sales and Marketing Organization positioning and selling in vitro diagnostics in Central Europe. The IFFMEDIC team has more than 10 years of experience in positioning molecular companion diagnostics. This has led to a key strategy of developing and positioning the acceptance of genetic cancer diagnostics to improve patients’ treatment.